|
|
SFX by Ex Libris Inc.
|
List of services to meet your request
|
||||||||
|
||||||||
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=sD66E0738-5FD0-11EF-97A6-078E85CE164B&I=39IZM&T=&OP=Display&O=html&O1=15816276&O2=4340000000116334&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3DOptimization%2520of%2520native%2520E.%2520coli-asparaginase%2520therapy%2520in%2520standard%2520risk-group%2520children%2520with%2520acute%2520lymphoblastic%2520leukemia%2520treated%2520by%2520the%2520ALL-MB%25202002%2520protocol%26rft.au%3DM.%2520Yu.%2520Goroshkova%26rft.date%3D2022-11-01%26rft.eissn%3D2413-4023%26rft.epage%3D33%26rft.externalDBID%3DDOA%26rft.externalDocID%3Doai_doaj_org_article_273ffc5c215a492e9db3020d5e11e678%26rft.genre%3Darticle%26rft.issn%3D1818-8346%26rft.issue%3D3%26rft.jtitle%3DOnkogematologii%25CD%25A1a%26rft.pub%3DABV-press%26rft.spage%3D25%26rft_id%3Dinfo%253Adoi%252F10.17650%252F1818-8346-2008-0-3-25-33%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-DOAJ_DIRECTORY_OPEN_ACCESS_JOURNALS-getFullTxt-object,2-EZB-FREE-00999_FREELY_AVAILABLE_EZB_JOURNALS-getFullTxt-object,3-DOI-getDOI-object,4-COBIB_SI_LCL-getHolding-object,5-REFWORKS_EXPORT_TOOL-getReference-object,6-GOOGLE_SCHOLAR_FREE-getWebSearch-object,7-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=1.155908&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:15816276-sD66E0738-5FD0-11EF-97A6-078E85CE164B" timestamp="2024-08-21T17:20:14Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:4340000000116334</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>Optimization of native E. coli-asparaginase therapy in standard risk-group children with acute lymphoblastic leukemia treated by the ALL-MB 2002 protocol</jnl:atitle>
<jnl:jtitle>Onkogematologiâ</jnl:jtitle>
<jnl:date>2022-11-01</jnl:date>
<jnl:spage>25</jnl:spage>
<jnl:epage>33</jnl:epage>
<jnl:issn>2413-4023</jnl:issn>
<jnl:issue>3</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>1818-8346</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:05dd78687f6698650ed33e4929ce9cf522f31924</ctx:identifier>
<ctx:identifier>urn:UUID:sD66E0738-5FD0-11EF-97A6-078E85CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)